Study Comparing Teclistamab, Talquetamab, and Drug Combination for Patients with Newly Diagnosed Multiple Myeloma Not Suitable for Stem Cell Transplant
This clinical trial is focused on studying treatments for Multiple Myeloma, a type of blood cancer that affects plasma cells in the bone marrow. The study will compare different combinations of medications to see which is more effective. The medications being tested include Teclistamab and Talquetamab, both used in combination with Daratumumab and Lenalidomide. Another group will receive a combination of Daratumumab, Lenalidomide, and Dexamethasone. These medications are given as injections or capsules.
The purpose of the study is to compare the effectiveness of these different treatment combinations in people who have been newly diagnosed with Multiple Myeloma and are not eligible for a stem cell transplant as their initial therapy. Participants will be randomly assigned to one of the treatment groups and will receive their assigned treatment over a period of time. The study will monitor the participants’ health and response to the treatment to determine which combination works best.
Throughout the study, participants will receive regular check-ups and monitoring to ensure their safety and to track the progress of the treatment. The study aims to provide valuable information on the best treatment options for people with Multiple Myeloma who cannot undergo a stem cell transplant.
1initial treatment phase
Upon joining the study, the patient will begin the initial treatment phase. This phase involves the administration of medications designed to treat multiple myeloma, a type of blood cancer.
The patient will receive a combination of medications, which may include teclistamab, talquetamab, daratumumab, lenalidomide, and dexamethasone. These medications are administered in different forms such as injections and oral capsules or tablets.
2medication administration
The patient will receive teclistamab and talquetamab as a solution for injection, administered subcutaneously, which means under the skin.
The patient will also take lenalidomide in the form of hard capsules, and dexamethasone in tablet form, both taken orally.
3treatment regimen
The treatment regimen involves a combination of these medications, with specific dosages and frequencies determined by the study protocol. The exact schedule will be provided by the healthcare team overseeing the trial.
The patient will continue this regimen for the duration specified by the study, which aims to evaluate the effectiveness of the treatment combinations.
4monitoring and assessment
Throughout the trial, the patient’s health and response to the treatment will be closely monitored. This includes regular check-ups and assessments to track progress and any side effects.
The primary goal is to compare the effectiveness of different treatment combinations in managing multiple myeloma.
5completion of trial
The trial is expected to continue until June 28, 2033. Upon completion, the patient’s overall response to the treatment will be evaluated.
The results will contribute to understanding the best treatment options for individuals with newly diagnosed multiple myeloma who are not candidates for stem cell transplant.
Who Can Join the Study?
Have a diagnosis of multiple myeloma, which is a type of blood cancer, according to specific medical guidelines.
Be newly diagnosed and not suitable for high-dose chemotherapy with autologous stem cell transplant (ASCT) because of:
Advanced age making it unsafe.
Other health conditions that could make the treatment difficult to handle.
Choosing to delay this type of treatment as the first option.
Have an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2, which is a way to measure how well you can perform daily activities.
Agree not to be pregnant, breastfeeding, or planning to become pregnant while in the study or for 6 months after the last treatment dose.
Agree not to plan to father a child while in the study or for 100 days after the last treatment dose.
Teclistamab is an investigational medication being studied for its potential to treat multiple myeloma. It is used in combination with other medications to see if it can help control the disease more effectively.
Daratumumab SC is a medication used to treat multiple myeloma. It is given as a subcutaneous injection, which means it is injected under the skin. It works by helping the immune system to attack and destroy cancer cells.
Lenalidomide is a medication that helps to slow down or stop the growth of cancer cells. It is often used in combination with other treatments for multiple myeloma to improve their effectiveness.
Talquetamab is another investigational medication being tested for its ability to treat multiple myeloma. It is used in combination with other drugs to determine if it can provide better outcomes for patients.
Dexamethasone is a type of steroid medication that helps reduce inflammation and suppress the immune system. In the context of multiple myeloma, it is used to help control symptoms and enhance the effects of other cancer treatments.
Multiple Myeloma – Multiple Myeloma is a type of blood cancer that affects plasma cells, which are a kind of white blood cell found in the bone marrow. In this disease, cancerous plasma cells multiply and accumulate in the bone marrow, leading to bone damage and affecting the production of normal blood cells. As the disease progresses, it can cause symptoms such as bone pain, frequent infections, anemia, and kidney problems. The abnormal plasma cells produce a large amount of a single type of antibody, which can be detected in the blood or urine. Over time, the accumulation of these cells and proteins can lead to complications affecting various organs and systems in the body.
The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Austria 
Belgium 
Czechia 
Denmark 
France 
Germany 
Greece 
Italy 
Norway 
Poland 
Portugal 
Spain 
Sweden 
The Netherlands